Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
2.050
-0.020 (-0.97%)
Apr 25, 2025, 4:00 PM EDT - Market closed
MRVI Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for MRVI stock have an average target of 6.54, with a low estimate of 2.50 and a high estimate of 13. The average target predicts an increase of 219.02% from the current stock price of 2.05.
Analyst Consensus: Hold
* Price targets were last updated on Mar 25, 2025.
Analyst Ratings
The average analyst rating for MRVI stock from 9 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 2 | 1 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 5 | 4 | 4 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 11 | 11 | 9 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +143.90% | Mar 25, 2025 |
| UBS | UBS | Hold Maintains $8 → $2.5 | Hold | Maintains | $8 → $2.5 | +21.95% | Mar 21, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +290.24% | Mar 3, 2025 |
| Baird | Baird | Buy → Hold Downgrades $9 → $3 | Buy → Hold | Downgrades | $9 → $3 | +46.34% | Feb 26, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $7 → $4.25 | Hold → Strong Sell | Downgrades | $7 → $4.25 | +107.32% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
196.64M
from 259.19M
Decreased by -24.13%
Revenue Next Year
224.62M
from 196.64M
Increased by 14.23%
EPS This Year
-0.26
from -1.05
EPS Next Year
-0.19
from -0.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 222.7M | 312.4M | 413.2M | ||
| Avg | 196.6M | 224.6M | 272.4M | ||
| Low | 181.3M | 197.5M | 210.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -14.1% | 58.9% | 83.9% | ||
| Avg | -24.1% | 14.2% | 21.3% | ||
| Low | -30.0% | 0.4% | -6.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.15 | -0.02 | 0.20 | ||
| Avg | -0.26 | -0.19 | -0.13 | ||
| Low | -0.41 | -0.40 | -0.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.